

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Elazar Rabbani et al.

Serial No. 08/978,633

Filed: November 25, 1997

Title: **NOVEL PROPERTY EFFECTING  
AND/OR PROPERTY EXHIBITING  
COMPOSITIONS FOR THERAPEUTIC  
AND DIAGNOSTIC USE**

Group Art Unit: 1635

Examiner Mary M. Schmidt



527 Madison Avenue, 9th Floor  
New York, New York 10022  
August 16, 1999

**FILED VIA FIRST CLASS MAIL**

Honorable Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

**Attention: Box Sequence**

**AMENDMENT IN CONNECTION WITH NOTICE  
TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES UNDER 37 C.F.R. §§1.821-1.825**

Dear Sirs:


Applicants are submitting this Amendment in connection with the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures referenced in the Office Action issued February 16, 1999 in connection with the instant application. While Applicants copy of the aforementioned Office Action did not contain the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, Applicants are nevertheless submitting this Amendment pursuant to the requirements of the Notice.

**PLEASE AMEND THIS APPLICATION AS FOLLOWS:**

**In the Specification:**

Page 23, after the last paragraph, kindly replace the sequence listing with the attached 13 pages inserted directly after this page and before page 24.

**ENZ-53(D1)**



Elazar Rabbani et al.

Serial No. 08/978,633

Filed: November 25, 1997

Page 2 (Amendment In Connection With Notice To Comply With Requirements For  
Patent Application Containing Nucleotide Sequence And/or Amino Acid  
Sequence Disclosures Under 37 C.F.R. §§1.821-1.825 - August 16,  
1999)


**REMARKS**

By this Amendment applicants are directing the entry of the paper copy of the accompanying "Sequence Listing" into the instant specification, thereby conforming with one of the requirements of the Notice To Comply With Sequence Listing.that should have been attached to the February 16, 12999 Office Action issued in connection with this application.

No fee is believed due in connection with this Amendment. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Amendment, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
(212) 583-0100

LC\USPros\ENZ53(d1)\amendmentresequence.081699.enz53D1

**ENZ-53(D1)**